Oct 26 (Reuters) - Britain's FTSE 100 index is seen opening 32 points lower at 5,828 on Monday, according to financial bookmakers. * ASTRAZENECA: AstraZeneca Plc has resumed the U.S. trial of its experimental COVID-19 vaccine after approval by regulators, and Johnson & Johnson is preparing to resume its trial on Monday or Tuesday, the companies said on Friday. * RIO TINTO: Global miner Rio Tinto is seeking court approval to sell its partner's share of diamonds from a mine in Canada's Northwest Territories, a filing this week showed, hoping to recover around C$120 million plus legal fees and other costs. * COCA COLA EUROPEAN PARTNERS: Coca-Cola Amatil Ltd said Coca-Cola European Partners offered to buy the Australian bottler for A$9.23 billion ($6.58 billion), in what would be the country's biggest deal this year. * UK REGULATORS: UK regulators are considering plans to allow banks to start paying dividends again next year, The Times newspaper reported on Monday. * GOLD: Gold prices fell to an over one-week low, as the dollar firmed and talks about the new U.S. coronavirus aid package showed no signs of progress. * OIL: Oil extended last week's losses, falling nearly 2% as a surge in COVID-19 infections in the United States and Europe prompted concern over crude demand, while the prospect of increased supply also hit sentiment. * The UK blue-chip index closed 1.3% higher on Friday, boosted by upbeat Barclays' earnings and rising hopes of a Brexit trade deal before year end, but the blue-chip FTSE 100 still logged its second weekly decline on concerns over fresh coronavirus restrictions. * UK CORPORATE DIARY: Kin and Carta Plc FY earnings PZ Cussons Plc Trading statement RPS Group Plc Q3 trading statement * For more on the factors affecting European stocks, please click on: TODAY'S UK PAPERS > Financial Times > Other business headlines (Reporting by Priyanshi Mandhan)
Our Standards: The Thomson Reuters Trust Principles.